-

Charles River Laboratories to Present at Morgan Stanley and Baird Conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

  • Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, at 10:00 a.m. ET; and
  • Baird 2026 Global Healthcare Conference on Tuesday, September 15th, at 9:40 a.m. ET.

Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for at least two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
Release Versions

Contacts

Investor Relations Contact:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced...

Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Medigen Vaccine Biologics Corp. (MVC) collaborate on the characterization and validation of the virus seed bank for MVC's next-generation multivalent enterovirus vaccine. Charles River will leverage its advanced analytical platforms, including Next-Generation Sequencing (NGS), to support critical steps of Chemistry, Manufacturing, and Controls (CMC) activities for MVC’s next-generation multivalent...

Charles River Laboratories Announces Second-Quarter 2026 Results

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financial Results...
Back to Newsroom